Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chia Tai Group is the China/Thailand branding associated with Charoen Pokphand Group, a large multinational conglomerate founded in 1921. The group is not primarily a biotech company; its core businesses span agri-food, retail, telecommunications, finance, real estate, and other sectors. It does, however, have a meaningful healthcare and pharmaceutical presence through CP Pharmaceutical Group and major subsidiaries such as Sino Biopharm, Chia Tai Tianqing, and Beijing Tide Pharmaceutical. In pharma, the group is active in research, manufacturing, and commercialization of biopharmaceuticals and chemical drugs, with strengths reported in oncology, liver disease, respiratory disease, surgery/analgesia, cardiovascular disease, gastrointestinal disorders, and urology. For a biotech analyst, the most relevant point is that Chia Tai Group is best understood as a diversified parent conglomerate with substantial downstream exposure to commercial pharmaceutical operations rather than as a pure-play drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chia Tai Group.